Selected articles
Articles for label Chlachula Lukáš are displayed.. Show all articles
Bevacizumab biosimilar – Mvasi® (ABP215)
02//2021 MUDr. Lukáš Chlachula
Monoclonal antibodies to various structures represent an important milestone in oncological treatment and form a clearly established group of anticancer therapy. However, we find their application in practically all fields of medicine. Bevacizumab is one of the first mass-established in oncology practice. However, there are also biosimilar drugs that are not identical generic copies of the reference drugs, but nevertheless have the same properties as the reference product. Mvasi® is the first FDA and EMA approved biosimilar for bevacizumab to treat a large group of cancers. Through a specific approval process (totality of evidence, TOE), it demonstrated the same properties, including efficacy, as the reference product (bevacizumab).
ENTIRE ARTICLE
Monoclonal antibodies to various structures represent an important milestone in oncological treatment and form a clearly established group of anticancer therapy. However, we find their application in practically all fields of medicine. Bevacizumab is one of the first mass-established in oncology practice. However, there are also biosimilar drugs that are not identical generic copies of the reference drugs, but nevertheless have the same properties as the reference product. Mvasi® is the first FDA and EMA approved biosimilar for bevacizumab to treat a large group of cancers. Through a specific approval process (totality of evidence, TOE), it demonstrated the same properties, including efficacy, as the reference product (bevacizumab).
Almost complete spontaneous regression of squamous cell lung cancer – case report
05/2020 MUDr. Lukáš Chlachula
Although both the incidence and mortality of lung cancers have tended to decline in recent years in the Czech Republic, they are still among the most common cancers in our country in both sexes. In recent years, we have been able to offer patients more and more products that use the natural properties of their own immune system to fight this insidious disease. The case documented below describes the spontaneous regression of a squamous cell lung tumor.
ENTIRE ARTICLE
Although both the incidence and mortality of lung cancers have tended to decline in recent years in the Czech Republic, they are still among the most common cancers in our country in both sexes. In recent years, we have been able to offer patients more and more products that use the natural properties of their own immune system to fight this insidious disease. The case documented below describes the spontaneous regression of a squamous cell lung tumor.
Ramucirumab in the treatment of gastric cancer
04/2020 MUDr. Lukáš Chlachula
Gastric cancer is one of the malignancies in the Czech Republic with a declining incidence over time and is the third most common cause of death from oncological diagnosis worldwide. The most common histological subtype is adenocarcinoma. The treatment of gastric adenocarcinomas is always complex, including surgery, chemotherapy, radiotherapy and targeted therapy. Ramucirumab is a monoclonal antibody against vascular endothelial growth factor receptor 2 (VEGFR-2), which blocks the binding of a specific ligand, thereby preventing signal transduction and triggering a signaling pathway leading to tumor neoangiogenesis. Efficacy has been described in two studies - RAINBOW and REGARD.
ENTIRE ARTICLE
Gastric cancer is one of the malignancies in the Czech Republic with a declining incidence over time and is the third most common cause of death from oncological diagnosis worldwide. The most common histological subtype is adenocarcinoma. The treatment of gastric adenocarcinomas is always complex, including surgery, chemotherapy, radiotherapy and targeted therapy. Ramucirumab is a monoclonal antibody against vascular endothelial growth factor receptor 2 (VEGFR-2), which blocks the binding of a specific ligand, thereby preventing signal transduction and triggering a signaling pathway leading to tumor neoangiogenesis. Efficacy has been described in two studies - RAINBOW and REGARD.
Radiotherapy, immunotherapy, abscopal effect. A new way?
01/2020 Special Edition - MUDr. Lukáš Chlachula
Radiotherapy is one of the methods of therapeutic armamentarium used in all stages of cancer. In the vast majority of cases, the indication of radiotherapy is local treatment of the tumor. The use of modern techniques can increase the effect while reducing the side effects. Numerous literature sources also describe the so-called abscopal effect - an immune-mediated response of non-irradiated tumor cells. The combination with immunotherapy, the so-called checkpoint inhibitors (anti-CTL, anti-PD-1 and anti-PD-LI), brings new possibilities in enhancing the complex tumor effect while using the abscopal effect.
ENTIRE ARTICLE
Radiotherapy is one of the methods of therapeutic armamentarium used in all stages of cancer. In the vast majority of cases, the indication of radiotherapy is local treatment of the tumor. The use of modern techniques can increase the effect while reducing the side effects. Numerous literature sources also describe the so-called abscopal effect - an immune-mediated response of non-irradiated tumor cells. The combination with immunotherapy, the so-called checkpoint inhibitors (anti-CTL, anti-PD-1 and anti-PD-LI), brings new possibilities in enhancing the complex tumor effect while using the abscopal effect.